RICHMOND, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a leading global robotic exoskeleton company, announced a new randomized comparative clinical trial is currently underway in Europe. The trial is called “The MOST Study” (Mobility improved after stroke when a robotic device was used in comparison to physical therapy) and is being initialized by Professor Dr. med. F. Hamzei, MD, MHBA, Chief physician of Department of Neurological Rehabilitation, Moritz Klinik. This study is investigating the impact of gait training with the Ekso GT™ on functional independence of 80 patients with impaired gait as a consequence of stroke, when compared to conventional physiotherapy alone.
“Based on our early observation, gait training with Ekso GT has shown to be a superior method over conventional physiotherapy techniques alone to improve rehabilitation of stroke patients,” said Professor Hamzei. “Stroke is one of the most common causes of chronic disability and can have long term debilitating effects. Intervening early and regularly with advanced assistive devices such as Ekso GT may significantly positively impact stroke patients’ overall motor recovery and help to regain or maintain their independence. That‘s our hypothesis in the ongoing randomized controlled study”.
Early observations from clinical use of Ekso GT for rehabilitation of stroke patients at Moritz Klinik led to the development of the MOST study. In this study the Ekso GT will be used daily in one group, while in the control group patients will be treated with conventional physiotherapy alone, in a daily training program, over the course of three weeks. The level of functional mobility will then be compared between both groups. The study is scheduled to conclude mid-year 2017.
“Early research suggests that Ekso GT, with our smart Variable Assist software, may help patients achieve better outcomes by providing an unparalleled opportunity for early mobilization and high intensity gait therapy,” said Thomas Looby, president and chief commercial officer. “It is exciting to see these early findings be the catalyst for a more significant study. We are pleased this trial is underway and eager to see the results.”
About Ekso Bionics
Ekso GT is a wearable bionic suit, which enables individuals with any amount of lower extremity weakness to stand up and walk. The device helps patients re-learn proper step patterns and weight shifts using a functional based platform. Shifts in the users’ weight activate sensors in the device, which initiate steps. Battery-powered motors then move the legs, supporting the user as needed to help them sustain balance and movement.
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. www.eksobionics.com
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Media Contact: Heidi Darling, Director of Marketing Communications Phone: 510-984-1761 x317 E-mail: email@example.com Investor Contact: Chad Rubin, Senior Vice President Phone: 646-378-2947 E-mail: firstname.lastname@example.org